Posted by Michael Wonder on 16 Jul 2024
Health Canada grants marketing authorisation for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for people with cystic fibrosis aged 2 years and older with certain rare mutations
15 July 2024 - Approximately 200 people with certain rare CF mutations are now eligible for Trikafta.
Vertex Pharmaceuticals today announced that Health Canada has granted marketing authorisation for the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis in patients aged 2 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive based on clinical and/or in vitro data.
